Clinical Trial Update: Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating cagrilintide for weight loss in people with overweight/obesity and type 2 diabetes is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight
• Type 2 Diabetes Mellitus

Drugs mentioned

• Cagrilintide (cagrilintide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Overweight, Obesity | Phase 3 | Status: ACTIVE_NOT_RECRUITING